GLP‑1s reshape markets

Weight-loss drugs are no longer just a pharmaceutical story; pills and higher-dose versions are pushing spending into gyms, beauty aisles, grocery carts, closets, and surgeons’ offices. (cnbc.com) Novo Nordisk’s Wegovy tablet was approved by the Food and Drug Administration in late 2025, and CNBC reported on April 7 that the pill’s January 2026 launch was drawing in new patients who had avoided injections because of needle fear or cost. The Food and Drug Administration also approved a higher-dose Wegovy injection, Wegovy HD, on March 19, 2026. (accessdata.fda.gov, cnbc.com, fda.gov) Eli Lilly is now in the same race with its oral obesity drug orforglipron, after phase 3 data published in The New England Journal of Medicine in September 2025 showed average weight loss of 11.2% at 72 weeks on the highest dose, versus 2.1% with placebo. Business Insider reported on April 11 that Lilly’s pill, sold as Foundayo, is one reason executives expect more users to enter the market. (nejm.org, businessinsider.com) These medicines mimic a gut hormone that slows digestion and reduces appetite, so users often eat less and lose weight over months. That can also mean less muscle, loose skin, hair thinning, and a need for new clothes, which is why the spending shift is showing up outside drugmakers. (fda.gov, businessinsider.com, finance.yahoo.com) Business Insider said one Ozempic user, Kelly Freeman, pays about $112 a month for the drug itself and estimated his total related spending at $700 to $1,000 a month after adding supplements, healthier food, an Apple Watch, a life coach, a physician, a trainer, and replacement clothing. That is the kind of household budget change retailers and service businesses are now trying to capture. (businessinsider.com) Gyms are pitching these users directly. Business Insider reported that Equinox launched a training and lifestyle program for people taking glucagon-like peptide-1 drugs, while Planet Fitness has published exercise guidance for them, and Morgan Stanley said in March that adoption is becoming “complementary to fitness.” (businessinsider.com, foodbusinessnews.net) Beauty chains are seeing the same pattern. Ulta Beauty chief executive Kecia Steelman said this month that demand is rising for anti-hairfall treatments and products aimed at skin elasticity as customers try to manage rapid-weight-loss side effects. (finance.yahoo.com) Grocers are adjusting, too. Business Insider reported that Albertsons’ chief executive said users are buying more chicken, beef, and fresh produce, and Albertsons now publishes a “GLP-1-friendly diet” guide centered on lean protein, vegetables, whole grains, and healthy fats. (businessinsider.com, albertsons.com) The medical knock-on effects are showing up elsewhere in health care. A Mass General Brigham study said anti-obesity glucagon-like peptide-1 prescribing rose 105.7% from 2022 to 2023 while bariatric surgery fell 8.7% in the same insured population, and other coverage of the same research highlighted a 25.6% drop in surgery among some cohorts. (massgeneralbrigham.org, beckershospitalreview.com) The next test is whether pills keep broadening the customer base after the first wave of injectable users. If they do, the businesses winning from glucagon-like peptide-1 drugs may include as many trainers, grocers, and dermatology-focused retailers as drug companies. (cnbc.com, jpmorgan.com)